
Latent EBV Boosts Anti-CD3 Therapy in Type 1 Diabetes
In a groundbreaking development that could redefine therapeutic strategies for Type 1 diabetes, researchers have uncovered a fascinating interplay between latent Epstein-Barr Virus (EBV) infection and the efficacy of anti-CD3 monoclonal antibody (mAb) …